Proteostasis Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers and develops novel therapeutics to treat cystic fibrosis and other diseases caused by an imbalance in the proteostasis network. Its lead product candidate is PTI-428, an orally bioavailable cystic fibrosis transmembrane conductance regulator modulator belonging to the amplifier class, which is in Phase II study. The company is also involved in developing PTI-801, a corrector molecule; and PTI-808, a potentiator molecule that have been completed Phase I Study. It has a collaboration agreement with Astellas Pharma Inc. Astellas Pharma, Inc. to research and identify therapies targeting the UPR pathway. The company was formerly known as Proteoguard, Inc. and changed its name to Proteostasis Therapeutics, Inc. in September 2007. Proteostasis Therapeutics, Inc. was founded in 2006 and is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PTI
Previous Symbol
CUSIPN/A
Phone617-225-0096
Debt
Debt-to-Equity RatioN/A
Current Ratio4.17
Quick Ratio4.17
Price-To-Earnings
Trailing P/E Ratio-2.42
Forward P/E Ratio-3.13
P/E GrowthN/A
Sales & Book Value
Annual Sales$5.34 million
Price / Sales39.11
Cash FlowN/A
Price / CashN/A
Book Value$2.08 per share
Price / Book2.74
Profitability
EPS (Most Recent Fiscal Year)($2.34)
Net Income$-59,430,000.00
Net Margins-1,307.84%
Return on Equity-104.17%
Return on Assets-72.93%
Miscellaneous
Employees52
Outstanding Shares36,700,000
Market Cap$225.32 million
OptionableOptionable
Proteostasis Therapeutics (NASDAQ:PTI) Frequently Asked Questions
What is Proteostasis Therapeutics' stock symbol?
Proteostasis Therapeutics trades on the NASDAQ under the ticker symbol "PTI."
How were Proteostasis Therapeutics' earnings last quarter?
Proteostasis Therapeutics Inc (NASDAQ:PTI) issued its quarterly earnings results on Wednesday, August, 8th. The company reported ($0.43) EPS for the quarter, missing analysts' consensus estimates of ($0.39) by $0.04. The business had revenue of $0.84 million for the quarter, compared to the consensus estimate of $1.16 million. Proteostasis Therapeutics had a negative net margin of 1,307.84% and a negative return on equity of 104.17%. View Proteostasis Therapeutics' Earnings History.
When is Proteostasis Therapeutics' next earnings date?
What price target have analysts set for PTI?
5 equities research analysts have issued 12-month target prices for Proteostasis Therapeutics' shares. Their predictions range from $5.00 to $25.00. On average, they expect Proteostasis Therapeutics' stock price to reach $14.6667 in the next year. This suggests a possible upside of 157.8% from the stock's current price. View Analyst Price Targets for Proteostasis Therapeutics.
What is the consensus analysts' recommendation for Proteostasis Therapeutics?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Proteostasis Therapeutics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Proteostasis Therapeutics.
What are Wall Street analysts saying about Proteostasis Therapeutics stock?
Here are some recent quotes from research analysts about Proteostasis Therapeutics stock:
- 1. According to Zacks Investment Research, "Proteostasis Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery and development of novel therapeutics to treat diseases caused by an imbalance in the proteostasis network primarily in the United States. Proteostasis Therapeutics, Inc. is based in Cambridge, Massachusetts. " (11/14/2018)
- 2. Cantor Fitzgerald analysts commented, "The Disclosure Section may be found on pages 43 – 45. We are initiating coverage of Proteostasis Therapeutics (PTI) with an Overweight rating and a 12- month price target of $21/share. Proteostasis is developing CFTR modulators for the treatment of cystic fibrosis. The company has a number of ongoing Phase 2 studies evaluating doublet and triplet proprietary drug combinations, with further studies assessing the drugs as add-on therapies to standard of care. In our view, cystic fibrosis is a well-understood disease that has received a magnitude of support from multiple CF foundations. We believe Vertex (Rated OW by Alethia Young) has ignited the engine with establishing proof of concept of this drug class, with three approved drugs." (11/6/2018)
- 3. HC Wainwright analysts commented, "Our price target of $15 is based on a probability-adjusted $12 from PTI-428 in F508del CF (12% discount rate, 2% growth rate, in line with the expected discount and growth parameters of a development-stage company) + $3 in cash. Risks to our investment thesis and target price include: (1) failure in clinical studies; (2) failure to secure regulatory approval; and (3) a smaller than anticipated commercial opportunity due to market size, competition, and/or pricing. Proteostasis Therapeutics, Inc." (10/18/2018)
Has Proteostasis Therapeutics been receiving favorable news coverage?
Headlines about PTI stock have been trending somewhat positive on Tuesday, InfoTrie Sentiment Analysis reports. The research firm scores the sentiment of media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Proteostasis Therapeutics earned a news sentiment score of 1.9 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 7.0 out of 10, indicating that recent media coverage is likely to have an effect on the stock's share price in the near future.
Are investors shorting Proteostasis Therapeutics?
Proteostasis Therapeutics saw a increase in short interest in the month of October. As of October 31st, there was short interest totalling 4,465,842 shares, an increase of 114.3% from the October 15th total of 2,083,696 shares. Based on an average daily trading volume, of 12,326,373 shares, the days-to-cover ratio is currently 0.4 days. Currently, 19.3% of the company's stock are sold short. View Proteostasis Therapeutics' Current Options Chain.
Who are some of Proteostasis Therapeutics' key competitors?
Some companies that are related to Proteostasis Therapeutics include Puma Biotechnology (PBYI), ImmunoGen (IMGN), Dicerna Pharmaceuticals (DRNA), Clovis Oncology (CLVS), Intra-Cellular Therapies (ITCI), Kiniksa Pharmaceuticals (KNSA), Akorn (AKRX), Deciphera Pharmaceuticals (DCPH), Y-mAbs Therapeutics (YMAB), Apellis Pharmaceuticals (APLS), Viking Therapeutics (VKTX), Athenex (ATNX), ProQR Therapeutics (PRQR), Aptinyx (APTX) and Revance Therapeutics (RVNC).
Who are Proteostasis Therapeutics' key executives?
Proteostasis Therapeutics' management team includes the folowing people:
- Ms. Meenu Chhabra, Pres, CEO & Director (Age 46)
- Dr. Benito Munoz, Chief Scientific Officer (Age 56)
- Dr. Po-Shun Lee, Exec. VP & Chief Medical Officer (Age 49)
- Dr. Marija Zecevic, Chief Operating Officer (Age 44)
- Ms. Janet L. Smart, VP of Intellectual Property & Legal Affairs (Age 61)
When did Proteostasis Therapeutics IPO?
(PTI) raised $51 million in an initial public offering on Thursday, February 11th 2016. The company issued 3,900,000 shares at a price of $12.00-$14.00 per share. Leerink Partners and RBC Capital Markets acted as the underwriters for the IPO and Baird and H.C. Wainwright & Co. were co-managers.
Who are Proteostasis Therapeutics' major shareholders?
Proteostasis Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Jennison Associates LLC (10.05%), Bailard Inc. (1.28%), Baird Financial Group Inc. (0.24%) and Morgan Stanley (0.11%). Company insiders that own Proteostasis Therapeutics stock include Cormorant Asset Management, Ll, Enterprise Associates 12 New, Fmr Llc, Franklin M Berger and Meenu Chhabra. View Institutional Ownership Trends for Proteostasis Therapeutics.
Which institutional investors are selling Proteostasis Therapeutics stock?
Which institutional investors are buying Proteostasis Therapeutics stock?
PTI stock was bought by a variety of institutional investors in the last quarter, including Baird Financial Group Inc. and Jennison Associates LLC. Company insiders that have bought Proteostasis Therapeutics stock in the last two years include Cormorant Asset Management, Ll, Enterprise Associates 12 New, Franklin M Berger and Meenu Chhabra. View Insider Buying and Selling for Proteostasis Therapeutics.
How do I buy shares of Proteostasis Therapeutics?
Shares of PTI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Proteostasis Therapeutics' stock price today?
One share of PTI stock can currently be purchased for approximately $5.69.
How big of a company is Proteostasis Therapeutics?
Proteostasis Therapeutics has a market capitalization of $225.32 million and generates $5.34 million in revenue each year. The company earns $-59,430,000.00 in net income (profit) each year or ($2.34) on an earnings per share basis. Proteostasis Therapeutics employs 52 workers across the globe.
What is Proteostasis Therapeutics' official website?
How can I contact Proteostasis Therapeutics?
Proteostasis Therapeutics' mailing address is 80 Guest Street Suite 500, Boston MA, 02135. The company can be reached via phone at 617-225-0096 or via email at [email protected]
MarketBeat Community Rating for Proteostasis Therapeutics (NASDAQ PTI)
MarketBeat's community ratings are surveys of what our community members think about Proteostasis Therapeutics and other stocks. Vote "Outperform" if you believe PTI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PTI will underperform the S&P 500 over the long term. You may vote once every thirty days.
